Therapeutic Modulation of Apoptosis: Targeting the BCL-2 Family at the Interface of the Mitochondrial Membrane.
10.3349/ymj.2008.49.5.689
- Author:
Kathleen N NEMEC
1
;
Annette R KHALED
Author Information
1. Biomolecular Science Center, Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32826, USA. akhaled@mail.ucf.edu
- Publication Type:Review ; Research Support, N.I.H., Extramural
- Keywords:
Apoptosis;
BAX;
BH3;
drug design;
peptide therapy
- MeSH:
Apoptosis/*drug effects/physiology;
BH3 Interacting Domain Death Agonist Protein/physiology;
Drug Design;
Genes, bcl-2;
Humans;
Mitochondria/physiology/ultrastructure;
Mitochondrial Membranes/*metabolism/physiology;
Multigene Family;
Proto-Oncogene Proteins c-bcl-2/*antagonists & inhibitors;
Signal Transduction
- From:Yonsei Medical Journal
2008;49(5):689-697
- CountryRepublic of Korea
- Language:English
-
Abstract:
A vast portion of human disease results when the process of apoptosis is defective. Disorders resulting from inappropriate cell death range from autoimmune and neurodegenerative conditions to heart disease. Conversely, prevention of apoptosis is the hallmark of cancer and confounds the efficacy of cancer therapeutics. In the search for optimal targets that would enable the control of apoptosis, members of the BCL-2 family of anti- and pro-apoptotic factors have figured prominently. Development of BCL-2 antisense approaches, small molecules, and BH3 peptidomimetics has met with both success and failure. Success-because BCL-2 proteins play essential roles in apoptosis. Failure-because single targets for drug development have limited scope. By examining the activity of the BCL-2 proteins in relation to the mitochondrial landscape and drawing attention to the significant mitochondrial membrane alterations that ensue during apoptosis, we demonstrate the need for a broader based multi-disciplinary approach for the design of novel apoptosis-modulating compounds in the treatment of human disease.
